Connect

Uncategorized

Uncategorized

Iowa to be Data Coordinating Center for Neuronext Clinical Trial

The National Institutes of Health (NIH) has selected the Network for Excellence in Neuroscience Clinical Trials network (NeuroNEXT), with the Cleveland Clinic as primary investigator and the University of Iowa as data coordinating center, to conduct a trial of a new drug for progressive multiple sclerosis (MS) patients. The Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of the oral drug ibudilast. This placebo-controlled trial seeks to enroll more than 250 patients at up to 28 clinical sites across the U.S.